Peptide and compounding law · Updated
Peptide regulatory status tracker: FDA approval and the 503A and 503B lists
Whether a clinic or pharmacy may use a peptide turns on a handful of federal lists that change through the year. Search a peptide to see where it stands on each, as of the date we last read them, with the source for every cell.
Peptide regulatory status tracker
30 peptides
| Peptide | FDA-approved product | 503A (pharmacies) | 503B (outsourcing facilities) | HHS draft policy, Oct. 2026 | Bottom line |
|---|---|---|---|---|---|
| AOD-9604AOD9604 | No FDA-approved product[8] | Nominated but withdrawn (previously Category 2): in no 503A category[4][1] | Not on the 503B bulks list or category list[5][7] | Not named in Appendix A as of November 2, 2026[15][16] | FDA says it has no, or only limited, safety information on AOD-9604 and has identified serious adverse events that may be associated with it, though causality is not clear. No FDA interim policy or HHS's draft covers compounding it. |
| BPC-157Body Protection Compound-157, BPC 157 | No FDA-approved product[8] | Nominated but withdrawn (previously Category 2): in no 503A category[4][1] | Not on the 503B bulks list or category list[5][7] | Named in Appendix A as of November 2, 2026 (HHS's draft enforcement-discretion policy, published Oct. 30, 2026; not final)[15][16] | Not approved, on neither bulks list, and outside FDA's interim policies. Under HHS's draft, HHS does not intend to take enforcement action against State-licensed pharmacies, Federal facilities or licensed physicians compounding it under section 503A; that is not approval, and it does not cover 503B outsourcing facilities or research-use sellers. Full guide |
| CJC-1295 | No FDA-approved product[8] | Nominated but withdrawn (previously Category 2): in no 503A category[4][1] | Not on the 503B bulks list or category list[5][7] | Not named in Appendix A as of November 2, 2026[15][16] | FDA's safety summary cites serious adverse events, including increased heart rate and a systemic vasodilatory reaction. No FDA interim policy or HHS's draft covers compounding it. |
| DihexaDihexa acetate | No FDA-approved product[8] | Nominated but withdrawn (previously Category 2): in no 503A category[4][1] | Not on the 503B bulks list or category list[5][7] | Not named in Appendix A as of November 2, 2026[15][16] | FDA says it has not identified any human exposure data on drug products containing dihexa acetate by any route. No FDA interim policy or HHS's draft covers compounding it. |
| DSIP (emideltide)Emideltide, Delta sleep-inducing peptide | No FDA-approved product[8] | Nominated but withdrawn (previously Category 2): in no 503A category[4][1] | Not on the 503B bulks list or category list[5][7] | Not named in Appendix A as of November 2, 2026[15][16] | FDA says it has not identified safety information on emideltide for the proposed route of administration. No FDA interim policy or HHS's draft covers compounding it. |
| Elamipretide (SS-31)SS-31, Forzinity | FDA-approved as Forzinity (elamipretide), September 19, 2025[11] | Not on the 503A bulks list or category list; elamipretide is a component of an FDA-approved drug (Forzinity), an ingredient route 503A recognizes when no USP or NF monograph exists, subject to the limit on copies of approved drugs[1][3][2][11][17] | Not on the 503B bulks list or category list[5][7] | Not named in Appendix A as of November 2, 2026[15][16] | Forzinity is a prescription drug approved, under accelerated approval, to improve muscle strength in patients with Barth syndrome who weigh at least 30 kg. Elamipretide is not on any FDA bulks or category list or in HHS's draft. |
| EpitalonEpithalon | No FDA-approved product[8] | Nominated but withdrawn (previously Category 2): in no 503A category[4][1] | Not on the 503B bulks list or category list[5][7] | Named in Appendix A as of November 2, 2026 (HHS's draft enforcement-discretion policy, published Oct. 30, 2026; not final)[15][16] | FDA says it has not identified safety information on epitalon for the proposed route, and no FDA interim policy covers it. Under HHS's draft, HHS does not intend to take enforcement action against 503A compounding with it; that is not approval and does not cover 503B outsourcing facilities. |
| GHK-CuCopper peptide, Copper tripeptide-1 | No FDA-approved product[8] | Category 1 (under evaluation), except for injectable routes; injectable GHK-Cu is nominated but withdrawn[1][4] | Not on the 503B bulks list or category list[5][7] | Not named in Appendix A as of November 2, 2026[15][16] | FDA does not intend to act against a 503A pharmacy compounding non-injectable GHK-Cu under its Category 1 interim policy, if the policy's conditions are met; injectable GHK-Cu has no such route. FDA says it intends to consult its compounding advisory committee on GHK-Cu before the end of February 2027. Full guide |
| GHRP-2Growth hormone releasing peptide-2, Pralmorelin | No FDA-approved product[8] | Category 3: Bulk Drug Substances Nominated Without Adequate Support[1][2] | Category 2 (significant safety risks) for injectable and nasal routes, since Sept. 29, 2023; Category 1 (under evaluation) for other routes[5][4] | Not named in Appendix A as of November 2, 2026[15][16] | Pharmacies have no FDA interim-policy route for GHRP-2, and injectable or nasal GHRP-2 is in 503B Category 2. Only an outsourcing facility using another route falls under FDA's 503B Category 1 policy, and only if that policy's conditions are met. |
| GHRP-6Growth hormone releasing peptide-6 | No FDA-approved product[8] | Category 3: Bulk Drug Substances Nominated Without Adequate Support[1][2] | Category 2: Bulk Drug Substances that Raise Significant Safety Risks (since Sept. 29, 2023)[5][4] | Not named in Appendix A as of November 2, 2026[15][16] | Neither FDA interim policy covers GHRP-6, and HHS's draft does not name it. FDA cites safety concerns including a potential effect on cortisol and increased blood glucose. |
| HexarelinExamorelin | No FDA-approved product[8] | Not on the 503A bulks list or category list[1][3] | Not on the 503B bulks list or category list[5][7] | Not named in Appendix A as of November 2, 2026[15][16] | Hexarelin is not on any FDA bulks or category list or in HHS's draft, and FDA stopped placing newly nominated substances into its interim categories on January 7, 2025, so none of these gives a pharmacy a route to compound it. |
| IpamorelinIpamorelin acetate | No FDA-approved product[8] | In no 503A category: FDA lists ipamorelin acetate as nominated but withdrawn[4][1] | Category 2: Bulk Drug Substances that Raise Significant Safety Risks (ipamorelin acetate, since Sept. 29, 2023)[5][4] | Not named in Appendix A as of November 2, 2026[15][16] | None of FDA's lists or HHS's draft gives a pharmacy or outsourcing facility a route to compound ipamorelin. FDA cites a published study that identified serious adverse events, including death, when ipamorelin was given intravenously. Full guide |
| Kisspeptin-10 | No FDA-approved product[8] | Category 2: Bulk Drug Substances that Raise Significant Safety Risks (since Sept. 29, 2023)[1][4] | Not on the 503B bulks list or category list[5][7] | Not named in Appendix A as of November 2, 2026[15][16] | FDA's interim policy does not cover a Category 2 substance, and FDA says it would consider taking action against a compounder using one under its general enforcement policies. Kisspeptin-10 is not approved and not in HHS's draft. |
| KPVLys-Pro-Val | No FDA-approved product[8] | Nominated but withdrawn (previously Category 2): in no 503A category[4][1] | Not on the 503B bulks list or category list[5][7] | Named in Appendix A as of November 2, 2026 (HHS's draft enforcement-discretion policy, published Oct. 30, 2026; not final)[15][16] | FDA says it has not identified any human exposure data on drug products containing KPV, and no FDA interim policy covers it. Under HHS's draft, HHS does not intend to take enforcement action against 503A compounding with it; that is not approval and does not cover 503B outsourcing facilities. |
| LL-37Cathelicidin LL-37 | No FDA-approved product[8] | Nominated but withdrawn (previously Category 2): in no 503A category[4][1] | Not on the 503B bulks list or category list[5][7] | Not named in Appendix A as of November 2, 2026[15][16] | FDA says nonclinical findings suggest harm to male reproduction and that LL-37 can promote tumors in some tissues. No FDA interim policy or HHS's draft covers compounding it. |
| Melanotan IIMT-II, MT-2 | No FDA-approved product[8] | Nominated but withdrawn (previously Category 2): in no 503A category[4][1] | Not on the 503B bulks list or category list[5][7] | Not named in Appendix A as of November 2, 2026[15][16] | FDA points to published case reports of serious adverse events, including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism. No FDA interim policy or HHS's draft covers compounding it. |
| MOTS-cMOTs-C | No FDA-approved product[8] | Nominated but withdrawn (previously Category 2): in no 503A category[4][1] | Not on the 503B bulks list or category list[5][7] | Named in Appendix A as of November 2, 2026 (HHS's draft enforcement-discretion policy, published Oct. 30, 2026; not final)[15][16] | FDA says it has not identified any human exposure data on drug products containing MOTS-c, and no FDA interim policy covers it. Under HHS's draft, HHS does not intend to take enforcement action against 503A compounding with it; that is not approval and does not cover 503B outsourcing facilities. Full guide |
| PT-141 (bremelanotide)Bremelanotide, Vyleesi | FDA-approved as Vyleesi (bremelanotide injection), NDA 210557, June 21, 2019[9] | Not on the 503A bulks list or category list; bremelanotide is a component of an FDA-approved drug (Vyleesi), an ingredient route 503A recognizes when no USP or NF monograph exists, subject to the limit on copies of approved drugs[1][3][2][9][17] | Not on the 503B bulks list or category list[5][7] | Not named in Appendix A as of November 2, 2026[15][16] | Vyleesi is a prescription drug approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder. An FDA warning letter of August 24, 2026 called "PT-141 Peptide (Bremelanotide)" sold online as a research peptide an unapproved new drug. Full guide |
| SelankSelank acetate, TP-7 | No FDA-approved product[8] | Nominated but withdrawn (previously Category 2): in no 503A category[4][1] | Not on the 503B bulks list or category list[5][7] | Not named in Appendix A as of November 2, 2026[15][16] | FDA says it lacks important information on any safety issues raised by selank acetate given to humans. No FDA interim policy or HHS's draft covers compounding it. |
| SemaxSemax (heptapeptide) | No FDA-approved product[8] | Nominated but withdrawn (previously Category 2): in no 503A category[4][1] | Not on the 503B bulks list or category list[5][7] | Named in Appendix A as of November 2, 2026 (HHS's draft enforcement-discretion policy, published Oct. 30, 2026; not final)[15][16] | FDA says it has no, or limited, safety information on Semax for the proposed routes, and no FDA interim policy covers it. Under HHS's draft, HHS does not intend to take enforcement action against 503A compounding with it; that is not approval and does not cover 503B outsourcing facilities. |
| SermorelinSermorelin acetate, Geref | No product on the market: Geref (sermorelin acetate) was FDA-approved and is discontinued, and FDA found it was not withdrawn for safety or effectiveness reasons[12][13] | Not on the 503A category list; FDA's 503B list marks sermorelin acetate as a component of FDA-approved drugs, an ingredient route 503A also recognizes when no USP or NF monograph exists[1][2][5] | Category 1 (under evaluation), marked as a component of FDA-approved drugs[5][6] | Not named in Appendix A as of November 2, 2026[15][16] | FDA does not intend to act against an outsourcing facility compounding with a 503B Category 1 substance such as sermorelin acetate if the interim policy's conditions are met. FDA's 2013 finding lets it approve generic versions of Geref, but no generic sermorelin has been approved. |
| TB-500Thymosin beta-4 fragment (LKKTETQ) | No FDA-approved product[8] | Nominated but withdrawn (previously Category 2): in no 503A category[4][1] | Not on the 503B bulks list or category list[5][7] | Named in Appendix A as of November 2, 2026 (HHS's draft enforcement-discretion policy, published Oct. 30, 2026; not final)[15][16] | FDA lists it as thymosin beta-4, fragment (LKKTETQ), says it has not identified any human exposure data, and gives it no interim-policy route. Under HHS's draft, HHS does not intend to take enforcement action against 503A compounding with it; that is not approval and does not cover 503B outsourcing facilities or research-use sellers. Full guide |
| TesamorelinEgrifta, Egrifta SV, Egrifta WR | FDA-approved as Egrifta (tesamorelin acetate); regulated as a biologic (BLA 022505) since March 23, 2020[10] | Not on the 503A category list; FDA says licensed biologics are not eligible for the 503A exemptions[1][14] | Not on the 503B lists; FDA says licensed biologics are not eligible for the 503B exemptions[5][7][14] | Not named in Appendix A as of November 2, 2026[15][16] | Egrifta is approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. Because it is now a licensed biologic, FDA's position is that sections 503A and 503B do not cover compounding it, and an August 24, 2026 FDA warning letter called a "Tesamorelin Research Peptide" an unapproved new drug. |
| Thymosin alpha-1Ta1, Thymalfasin | No FDA-approved product[8] | Nominated but withdrawn (previously Category 2): in no 503A category[4][1] | Category 3: Bulk Drug Substances Nominated Without Adequate Support[5][6] | Not named in Appendix A as of November 2, 2026[15][16] | Neither FDA interim policy covers thymosin alpha-1, and HHS's draft does not name it. FDA says the safety information is inadequate for it to understand the extent of any safety issues. |
| VIP (vasoactive intestinal peptide)Vasoactive intestinal peptide, Aviptadil | No FDA-approved product[8] | Category 1: Bulk Drug Substances Under Evaluation[1][2] | Not on the 503B bulks list or category list[5][7] | Not named in Appendix A as of November 2, 2026[15][16] | FDA does not intend to act against a 503A pharmacy compounding with VIP while it stays in Category 1, if the interim policy's conditions are met, including a valid certificate of analysis and an FDA-registered manufacturer. That is not approval, and outsourcing facilities have no listed route for it. |
| SemaglutideOzempic, Wegovy, Rybelsus | FDA-approved as Ozempic, Wegovy and Rybelsus[8] | Not on the 503A category list; with the shortage over, FDA limits compounded copies of the approved drugs[1][17][19] | Not on the 503B bulks list; FDA proposed on May 1, 2026 not to add it (not final)[7][20] | Not named in Appendix A as of November 2, 2026[15][16] | FDA declared the semaglutide injection shortage resolved on February 21, 2025, so outsourcing facilities have no route to compound it from bulk, and 503A pharmacies may not compound copies regularly or in inordinate amounts unless a prescriber documents a significant difference for the patient. FDA says salt forms such as semaglutide sodium and acetate have no known lawful basis in compounding. Full guide |
| TirzepatideMounjaro, Zepbound | FDA-approved as Mounjaro and Zepbound[8] | Not on the 503A category list; with the shortage over, FDA limits compounded copies of the approved drugs[1][17][19] | Not on the 503B bulks list; FDA proposed on May 1, 2026 not to add it (not final)[7][20] | Not named in Appendix A as of November 2, 2026[15][16] | FDA declared the tirzepatide injection shortage resolved on December 19, 2024, and its grace periods ended in March 2025. Outsourcing facilities now have no route to compound it from bulk, and 503A pharmacies may not compound copies regularly or in inordinate amounts unless a prescriber documents a significant difference for the patient. Full guide |
| LiraglutideVictoza, Saxenda | FDA-approved as Victoza, Saxenda and generic liraglutide injections[8] | Not on the 503A category list[1] | Not on the 503B bulks list (FDA proposed on May 1, 2026 not to add it; not final), but liraglutide injection is on FDA's shortage list[7][20][19] | Not named in Appendix A as of November 2, 2026[15][16] | Liraglutide injection is still on FDA's drug shortage list (first posted July 18, 2023), and while it stays there section 503B's shortage route lets an outsourcing facility compound it from bulk, subject to the law's other conditions. That route closes when the shortage ends, and FDA has proposed (not final) not to add liraglutide to the 503B bulks list. |
| CagrilintideCagriSema | No FDA-approved product[8][18] | Not on the 503A lists; FDA says it cannot be used in compounding under federal law[1][18] | Not on the 503B lists; FDA says it cannot be used in compounding under federal law[5][7][18] | Not named in Appendix A as of November 2, 2026[15][16] | FDA says cagrilintide "cannot be used in compounding under federal law", is not a component of an FDA-approved drug and has not been found safe and effective for any condition. |
| RetatrutideLY3437943 | No FDA-approved product[8][18] | Not on the 503A lists; FDA says it cannot be used in compounding under federal law[1][18] | Not on the 503B lists; FDA says it cannot be used in compounding under federal law[5][7][18] | Not named in Appendix A as of November 2, 2026[15][16] | FDA says retatrutide "cannot be used in compounding under federal law" and has warned telehealth companies marketing it, ingredient distributors selling it to compounders and outsourcing facilities repackaging it. |
No peptide in the table matches. We list only peptides we have checked at the source; ask us about one that is missing.
The table gives each peptide's federal status on FDA's and HHS's own lists, checked at the source on November 17, 2026 (HHS's Appendix A as last read on November 2, 2026); it is general information, not legal advice, and state pharmacy and medical rules can be stricter.
Sources for the table
- FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (category list) (as of May 14, 2026)
- FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (as of May 14, 2026)
- 21 CFR 216.23, the 503A bulks list (eCFR) (as of November 13, 2026)
- FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2 and nominated-but-withdrawn tables) (as of April 22, 2026)
- FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503B (category list) (as of March 21, 2025)
- FDA, Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act (as of January 7, 2025)
- FDA, 503B Bulk Drug Substances List (as of May 16, 2024)
- FDA, Drugs@FDA (searched through openFDA's Drugs@FDA data) (as of November 16, 2026)
- FDA, Drugs@FDA, NDA 210557 (Vyleesi, bremelanotide) (as of November 17, 2026)
- FDA, Drugs@FDA, BLA 022505 (Egrifta, tesamorelin) (as of November 17, 2026)
- FDA, Drugs@FDA, NDA 215244 (Forzinity, elamipretide) (as of November 17, 2026)
- FDA, Drugs@FDA, NDA 019863 (Geref, sermorelin acetate) (as of November 17, 2026)
- FDA, Determination That GEREF (Sermorelin Acetate) Injection ... Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness, 78 FR 14095 (Mar. 4, 2013) (as of March 4, 2013)
- FDA, Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application (guidance, January 2018)
- HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, 91 FR 68526 (Oct. 30, 2026; draft) (as of October 30, 2026)
- HHS, the draft policy with Appendix A (hhs.gov PDF; Appendix A as read November 2, 2026) (as of November 2, 2026)
- FDA, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (as of April 1, 2026)
- FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (as of October 1, 2026)
- FDA Drug Shortages database (as of November 17, 2026)
- FDA, proposal not to include semaglutide, tirzepatide and liraglutide on the 503B Bulks List, 91 FR 23431 (May 1, 2026) (as of May 1, 2026)
- FDA warning letter, NuScience Peptides LLC, Cornelius, NC (Aug. 24, 2026) (as of August 24, 2026)
What each column means
- FDA-approved product: whether a finished drug containing the peptide has FDA approval, and its name. Approval covers that product, not every use of the molecule.
- 503A: whether a state-licensed pharmacy or physician compounding for an individual patient may use the peptide as a bulk drug substance, including where FDA has placed it among the nominated substances it is still evaluating.
- 503B: the same question for outsourcing facilities registered with FDA.
- HHS draft policy: whether the peptide is named in the draft enforcement-discretion policy HHS published in October 2026. A draft is not binding and may change.
How we keep it current
We check these lists in a regular watch of FDA, HHS and the Federal Register. When one changes, the table and the guide for that peptide change with it, and the date shown on the page moves.
What the table cannot tell you
- Whether a particular product may be sold as it is: labeling, marketing claims and who prescribes it matter as much as the lists. See advertising peptides and compounded drugs.
- State pharmacy and medical board rules, which add limits of their own.
- Anything that changed after the date shown.
Common questions
If a peptide is allowed on a 503A list, is it legal to sell?
Not by that alone. A 503A list says whether a pharmacy may use the substance as a bulk ingredient when it compounds for an identified patient on a prescription. It does not approve the peptide, its labeling or a clinic's marketing. Are peptides legal? walks through the rest.
What is the difference between 503A and 503B?
503A covers state-licensed pharmacies and physicians compounding for individual patients on prescriptions; 503B covers outsourcing facilities that register with FDA and meet its manufacturing standards. Each has its own bulk substance lists. 503A vs 503B compares them.
Does HHS's draft policy make these peptides legal to compound?
No. It is a draft that HHS published for comment in October 2026. It says it does not establish any rights and is not binding on HHS or the public, and HHS may revisit it, for example if a safety signal arises. For the peptides it names, HHS says only that it does not intend to take enforcement action against 503A compounding with them; that is not approval, and it does not reach 503B outsourcing facilities.
Why is a peptide missing from the table?
We list only peptides whose status we have checked at each source. Ask us about one that is missing and we will check it.
Cite or embed this tool
Newsletters, associations and reporters are welcome to cite the tool or put it on their own pages. Please credit DPS Law with a link to this page.
Citation
DPS Law, “Peptide regulatory status tracker,” updated November 17, 2026, https://dpslaw.com/tools/peptide-status-tracker.
Related
- Which peptides are FDA-approved? The FDA's lists explained
- 503A vs 503B
- Are peptides legal?
- Peptide attorney in Charlotte, NC
More tools
Not sure where your peptide program stands?
DPS Law advises clinics, physicians and pharmacies on North Carolina and federal compounding law. For another state's pharmacy or medical board rules, talk to a lawyer licensed in that state.